{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown","Transcriptomics","Genomics","Proteomics"],"submitter":["Ryo Honda"],"study_type":["transcription profiling by array"],"organism":["Homo sapiens"],"species":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-16847"],"description":["Human pancreatic cancer cells (PANC-1) were treated with a protein-based pan-RAS inhibitor (RRSP-RBD-TAT), a control construct (RRSP-TAT), or vehicle control. After 48 hours of treatment, total RNA was extracted and subjected to gene expression profiling using Agilent SurePrint G3 Human GE 8x60K microarrays. The objective of this experiment was to characterize transcriptional changes associated with RAS pathway inhibition and to compare the molecular effects of RRSP-RBD-TAT with control treatments. Raw intensity data were processed and used for downstream analyses including gene set enrichment analysis (GSEA)."],"repository":["biostudies-arrayexpress"],"sample_protocol":["Labeling - RNA labeling was performed using Agilent one-color labeling protocol with Cy3 according to the manufacturer’s instructions.","Hybridization - Labeled RNA was hybridized onto Agilent SurePrint G3 Human GE 8x60K microarrays according to the manufacturer’s protocol.","Sample Collection - After treatment, cells were washed with PBS and lysed for RNA extraction.","Nucleic Acid Extraction - Total RNA was extracted using standard procedures and purified according to the manufacturer’s instructions. RNA quality was assessed prior to microarray analysis.","Scaning - Microarray slides were scanned using an Agilent DNA Microarray Scanner (G2505C) at 3 µm resolution according to the manufacturer’s instructions."],"figure_sub":["MIAME Score","Raw Data","Organization","Assays and Data","MAGE-TAB Files","Array Designs"],"pubmed_authors":["Ryo Honda"],"additional_accession":[]},"is_claimable":false,"name":"Gene expression profiling of human pancreatic cancer cells treated with RRSP-RBD-TAT and RRSP-TAT compared with untreated controls","description":"Human pancreatic cancer cells (PANC-1) were treated with a protein-based pan-RAS inhibitor (RRSP-RBD-TAT), a control construct (RRSP-TAT), or vehicle control. After 48 hours of treatment, total RNA was extracted and subjected to gene expression profiling using Agilent SurePrint G3 Human GE 8x60K microarrays. The objective of this experiment was to characterize transcriptional changes associated with RAS pathway inhibition and to compare the molecular effects of RRSP-RBD-TAT with control treatments. Raw intensity data were processed and used for downstream analyses including gene set enrichment analysis (GSEA).","dates":{"release":"2026-05-02T00:00:00Z","modification":"2026-05-02T03:21:14.554Z","creation":"2026-04-02T10:09:59.445Z"},"accession":"E-MTAB-16847","cross_references":{"EFO":["EFO_0002768","EFO_0002944","EFO_0003814","EFO_0003813","EFO_0005518","EFO_0003815"]}}